Publicaciones en colaboración con investigadores/as de Hospital General Universitario Reina Sofía (19)

2023

  1. Midazolam versus morphine in acute cardiogenic pulmonary edema patients with and without atrial fibrillation: findings from the MIMO trial

    European journal of emergency medicine : official journal of the European Society for Emergency Medicine, Vol. 30, Núm. 2, pp. 78-84

  2. Effects of midazolam vs morphine in patients with acute pulmonary edema with left ventricular systolic dysfunction: a secondary analysis of data from the MIMO trial

    Emergencias, Vol. 35, Núm. 1, pp. 25-30

  3. Antithrombotic Strategy in Secondary Prevention for High-Risk Patients with Previous Acute Coronary Syndrome: Overlap between the PEGASUS Eligibility and the COMPASS Eligibility in a Large Multicenter Registry

    American Journal of Cardiovascular Drugs, Vol. 23, Núm. 1, pp. 77-87

2022

  1. Safety and efficacy of different P2Y12 inhibitors in patients with acute coronary syndromes stratified by the PRAISE risk score: a multicentre study

    European heart journal. Quality of care & clinical outcomes, Vol. 8, Núm. 8, pp. 881-891

  2. Midazolam versus morphine in acute cardiogenic pulmonary oedema: results of a multicentre, open-label, randomized controlled trial

    European Journal of Heart Failure, Vol. 24, Núm. 10, pp. 1953-1962

2021

  1. Ticagrelor or Clopidogrel After an Acute Coronary Syndrome in the Elderly: A Propensity Score Matching Analysis from 16,653 Patients Treated with PCI Included in Two Large Multinational Registries

    Cardiovascular Drugs and Therapy, Vol. 35, Núm. 6, pp. 1171-1182

  2. Machine learning-based prediction of adverse events following an acute coronary syndrome (PRAISE): a modelling study of pooled datasets

    The Lancet, Vol. 397, Núm. 10270, pp. 199-207

2020

  1. P2Y12 inhibitors in acute coronary syndrome patients with renal dysfunction: an analysis from the RENAMI and BleeMACS projects

    European heart journal. Cardiovascular pharmacotherapy, Vol. 6, Núm. 1, pp. 31-42

  2. Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry

    European Journal of Preventive Cardiology, Vol. 27, Núm. 7, pp. 696-705

  3. Identification of Senior At Risk scale predicts 30-day mortality among older patients with acute heart failure

    Medicina Intensiva, Vol. 44, Núm. 1, pp. 9-17

  4. Efficacy and Safety of Clopidogrel, Prasugrel and Ticagrelor in ACS Patients Treated with PCI: A Propensity Score Analysis of the RENAMI and BleeMACS Registries

    American Journal of Cardiovascular Drugs, Vol. 20, Núm. 3, pp. 259-269

  5. Comparative external validation of the PRECISE-DAPT and PARIS risk scores in 4424 acute coronary syndrome patients treated with prasugrel or ticagrelor

    International Journal of Cardiology, Vol. 301, pp. 200-206

  6. Average daily ischemic versus bleeding risk in patients with ACS undergoing PCI: Insights from the BleeMACS and RENAMI registries

    American Heart Journal, Vol. 220, pp. 108-115

2018

  1. Incidence and predictors of bleeding in ACS patients treated with PCI and prasugrel or ticagrelor: An analysis from the RENAMI registry

    International Journal of Cardiology, Vol. 273, pp. 29-33

2017

  1. Usefulness of Early Treatment With Melatonin to Reduce Infarct Size in Patients With ST-Segment Elevation Myocardial Infarction Receiving Percutaneous Coronary Intervention (From the Melatonin Adjunct in the Acute Myocardial Infarction Treated With Angioplasty Trial)

    American Journal of Cardiology, Vol. 120, Núm. 4, pp. 522-526

  2. Effect of intravenous and intracoronary melatonin as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: Results of the Melatonin Adjunct in the acute myocaRdial Infarction treated with Angioplasty trial

    Journal of Pineal Research, Vol. 62, Núm. 1

2016

  1. Thrombus aspirated from patients with ST-elevation myocardial infarction: Association between 3-nitrotyrosine and inflammatory markers – Insights from ARTERIA study

    International Journal of Medical Sciences, Vol. 13, Núm. 7, pp. 477-482

2010

  1. Letter by dominguez-rodriguez et al regarding article, "c-reactive protein and the risk of stent thrombosis and cardiovascular events after drug-eluting stent implantation"

    Circulation

2009

  1. Randomised, double-blind, placebo-controlled trial of ivabradine in patients with acute coronary syndrome: Effects of the i f current inhibitor ivabradine on reduction of inflammation markers in patients with acute coronary syndrome-RIVIERA trial study design and rationale

    Cardiovascular Drugs and Therapy, Vol. 23, Núm. 3, pp. 243-247